Tamargo B, Rosario LA, Batista N, Arencibia DF, Fernández K, Villegas A, Ayala JA, Gustavo SV

Language: Spanish
References: 21
Page: 3-9
PDF size: 256.65 Kb.

ABSTRACT

Whole cell Leptospirosis vaccines have been developed and used from the 20´s of last century up today , most of them are not adjuvated and do not confer a long-lasting immunity. These vaccines are mainly against different serogroups of Leptospira interrogans contained in the preparation. Though several attempts to obtain a vaccinal formulation more effective, purer, with wider spectrum and longer protection than the bacterines of inactivated whole cells have been made no vaccine with these characteristics have been registered yet. This paper deals with the obtainment of outer membrane antigens from a Cuban autochthonous strain (Strain 87, L. interrogans serovar Canicola), by a modification of the technology for the production of outer membrane vesicles, patented by researchers from Finlay institute These antigens with nanoproteoliposomic structure were formulated/adjuvated by different strategies, obtaining five preparations with cochlear structures which are nanoparticles of approximately 100 to 150 nm of lenght and from 15 to 30 nm of diameter. Two doses of the immunogens are inoculated in the biomodel Mesocrisetus aureatus, with an interval of six weeks. The challenge was carried out with 100.000 DL50. Results showed that the new vaccinal formulations confer protection against the homologous challenge and were able to eliminate the carrier status. This, together with the robutness of the preparation method, the higher level of purity, compared to the bacterines, and the no need of aluminium hydroxide make the formulations an alternative of interest for continuing their development.

REFERENCES

1. OPS. Organización Panamericana de la Salud. 14a Reunión Interamericana a nivel Ministerial en Salud y Agricultura. Las enfermedades desatendidas en las poblaciones postergadas, con énfasis en las zoonosis. 2005:14-8. Disponible en: http:// www.paho.org/spanish/ad/dpc/vp/rimsa14-18-s.pdf.

2. Wang Z, Jin L, Wêgrzyn A. Leptospirosis vaccines. Microbial Cell Factories 2007;6:39. Disponible en: http://www.microbialcellfactories.com/content/6/1/39.

3. Adler B, De la Peña M. Leptospira and Leptospirosis. Vet Microbiol 2009;2:4382-92.

4. Haake D, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. Infect Immun 2002;70:4936-45.

5. González M, Martínez R, Cruz R, Infante J, González I, Baró M, et al. Vax-SPIRAL®. Vacuna antileptospirósica trivalente parauso humano, investigación, desarrollo e impacto sobre la enfermedad en Cuba. Biotec Aplic 2004;2(2):107-11.

6. McBride A, Athanazio D, Reis M, Ko A. Leptospirosis. Curr Opin Infect Dis 2005;18:376-86.

7. Martínez R, Pérez A, Quiñones M, Cruz R, Álvarez A, Armesto M, et al. Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba. Rev Panam Salud Pública 2004;15:249-55.

8. Yang C, Wu M, Pan M, Hsieh W. Vandewalle A, Huang CC. The Leptospira outer membrane protein LipL32 induces tubulointerstitial nephritis-mediated gene expression in mouse proximal tubule cells. J Am Soc Nephrol 2002;13:2037-45.

9. Silva E, Santo C, Athanazio D, Seyffert N, Seixas F, Cerqueira GM, et al. Characterization of virulent Leptospira isolates in hamster model. Vaccine 2008;36:56-62.

10. European Commission. “Guide to Good Manufacturing Practice for Medicinal Products and Active Pharmaceutical Ingredients. Annex 13 Manufactures of Investigational Medicinal Products”. Brussels: European Commission Enterprise Directorate General; 2003.

11. Campa C, Sierra VG, Gutiérrez MM, Vázquez G, Jorrín LG, García L, et al, inventors. Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method. US patent 5,597,572. 1997 Jan. 28.

12. Kirby C, Gregoriadis G. Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes. Nature Biotechnology 1984;2:979-84.

13. Zarif L, Mannino RJ. Cochleates: lipid-based vehicles for gene delivery-concept, achievements and future development. In N. Habib (ed.). Cancer gene therapy: past achievements and future challenges. London: Plenum Publishing Company; 2000 p.83-94.

14. Servicio Nacional de Sanidad Animal. Cuba. Disposición 309/ 2000. Consideraciones éticas para el uso de animales de laboratorio: (Documento regulatorio). La Habana: Servicio Nacional de Sanidad Animal; 2000.

15. Acevedo R, Callicó A, Del Campo J, González E, Cedré B, González L, et al. Intranasal administrations of proteoliposomederived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 2009;49:309-15.

16. Pérez O, Lastre M, Bracho G, del Campo J, Zayas C, Acevedo R, et al. Natural Neisseria derive proteoliposome and cochleate as potent vaccine adjuvants. Pharmacology online 2006;3:762-4.

17. Nunes-Edward PL, Thierman AB, Bassford PJ and Stramam LV. Identification and characterization of the protein antigens of Leptospira interrogans serovar Hardjo. Infect Immun 1985;48:492-7.

18. Machado M, Naranjo M, González M, Batista N, González A, Abreu Y, et al. Inmunoprotección de componentes de membrana externa de Leptospira pomona serovar Mozdok. VacciMonitor 2007;16(2):7-15.

19. Rodríguez Y, González M, Naranjo M, González I, Oliva R y Fariñas M. Evaluación de la capacidad inmunogénica y protectora de componentes extracelulares de Leptospira interrogans serovar Canícola. VacciMonitor 1997;6(7):11-4.

20. Palaniappan R, McDonough S, Divers T, Chen Ch, Pan M, Matsumoto M, et al. Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans serovar Pomona Infection. Infect Immu 2006;74:1745-50.

21. Maneewatch S, Tapchaisri P, Sakolvaree Y, Klaysing B, Tongtawe P. OmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. Challenge. Asian Pac J Allergy Immunol 2007;25(1):75-82.